Indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intra-hepatic artery chemotherapy of floxuridine
Boston Scientific Corporation
TheraSphere Y-90 Glass Microspheres
Glass
Y-90 (integral to the glass matrix)
25 ± 10
3.3
Approximately 0.25 million per GBq at calibration (3 GBq vial contains approximately 0.75 million microspheres)
Standard dose sizes: 3, 5, 7, 10, 15, 20; custom dose sizes: available in 0.5 increments, between 3–20 (activity/microsphere at calibration is approximately 4,000 Bq)
Indicated for use in radiation treatment or as a neoadjuvant to surgery or transplantation in patients with unresectable hepatocellular carcinoma who can have placement of appropriately positioned hepatic arterial catheters; also indicated for hepatocellular carcinoma patients with partial or branch portal vein thrombosis/occlusion, when clinical evaluation warrants the treatment
Advertisement
Advertisement
We value keeping the Device Guide up to date.
If you want to add or update your company’s device listings, please let us know!